DaVita Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), DaVita Inc. reported revenue of $13.6B (+6.5% year on year) and net income of $1.1B (-13.8% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Dialysis patient service revenues | $13.0B | $12.3B | $11.6B | $11.2B |
| Other revenues | $635.9M | $555.2M | $565.2M | $433.4M |
| Total revenues | $13.6B | $12.8B | $12.1B | $11.6B |
| Patient care costs | $9.2B | $8.6B | $8.3B | $8.2B |
| General and administrative | $1.7B | $1.5B | $1.5B | $1.4B |
| Depreciation and amortization | $715.3M | $723.9M | $745.4M | $732.6M |
| Equity investment income, net | ($33.0M) | ($26.2M) | ($27.9M) | ($26.5M) |
| Goodwill impairment charges | $0 | $0 | $26.1M | — |
| Gain on changes in ownership interests | $0 | ($109.5M) | — | — |
| Total operating expenses | $11.6B | $10.7B | $10.5B | $10.3B |
| Operating income | $2.0B | $2.1B | $1.6B | $1.3B |
| Debt expense | ($579.9M) | ($470.5M) | ($398.6M) | ($357.0M) |
| Debt extinguishment and modification costs | ($14.2M) | ($19.8M) | ($8.0M) | — |
| Other loss, net | ($102.7M) | ($69.8M) | ($19.2M) | ($15.8M) |
| Income from continuing operations before income taxes | $1.3B | $1.5B | $1.2B | $966.3M |
| Income tax expense | $293.1M | $279.7M | $220.1M | $198.1M |
| Net income from continuing operations | $1.1B | $1.3B | $957.0M | $768.2M |
| Net income from discontinued operations, net of tax | $25.0M | $0 | $0 | $13.5M |
| Net income | $1.1B | $1.3B | $957.0M | $781.6M |
| Less: Net income attributable to noncontrolling interests | ($331.9M) | ($314.4M) | ($265.4M) | ($221.2M) |
| Basic net income from continuing operations | $9.72 | $11.02 | $7.62 | $5.88 |
| Basic net income | $10.06 | $11.02 | $7.62 | $6.03 |
| Diluted net income from continuing operations | $9.51 | $10.73 | $7.42 | $5.71 |
| Diluted net income | $9.84 | $10.73 | $7.42 | $5.85 |
| Basic shares (in shares) | 74.2M | 85.0M | 90.8M | 93.0M |
| Diluted shares (in shares) | 75.9M | 87.3M | 93.2M | 95.8M |
| Net income from continuing operations | $721.8M | $936.3M | $691.5M | $546.9M |
| Net income from discontinued operations | $25.0M | $0 | $0 | $13.5M |
| Net income attributable to DaVita Inc. | $746.8M | $936.3M | $691.5M | $560.4M |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Dialysis patient service revenues | $3.4B | $3.3B | $3.3B | $3.2B |
| Other revenues | $187.7M | $142.8M | $122.1M | $172.7M |
| Total revenues | $3.6B | $3.4B | $3.4B | $3.4B |
| Patient care costs | $2.4B | $2.3B | $2.3B | $2.3B |
| General and administrative | $423.5M | $421.9M | $414.4M | $412.8M |
| Depreciation and amortization | $167.8M | $177.8M | $177.5M | $174.7M |
| Equity investment income, net | ($8.2M) | ($8.3M) | ($10.2M) | ($7.4M) |
| Total operating expenses | $3.0B | $2.9B | $2.9B | $2.8B |
| Operating income | $579.0M | $481.9M | $505.8M | $537.8M |
| Debt expense | ($150.3M) | ($145.1M) | ($150.6M) | ($146.1M) |
| Debt extinguishment and modification costs | ($2.0M) | — | ($5.2M) | — |
| Other income (loss), net | $8.3M | $4.5M | ($41.3M) | ($22.9M) |
| Income before income taxes | $435.0M | $341.2M | $308.8M | $368.9M |
| Income tax expense | $91.8M | $66.2M | $68.6M | $93.7M |
| Net income | $343.2M | $275.0M | $240.2M | $275.2M |
| Less: Net income attributable to noncontrolling interests | ($77.8M) | ($77.5M) | ($89.9M) | ($75.9M) |
| Net income attributable to DaVita Inc. | $265.4M | $197.5M | $150.3M | $199.3M |
| Basic net income | $4.10 | $2.93 | $2.09 | $2.62 |
| Diluted net income | $4.02 | $2.87 | $2.04 | $2.58 |
| Basic shares | 64.8M | 67.4M | 72.1M | 75.9M |
| Diluted shares | 66.1M | 68.9M | 73.8M | 77.4M |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $676.4M | $794.9M | $380.1M | $244.1M |
| Restricted cash and equivalents | $81.3M | $84.9M | $84.6M | $94.9M |
| Short-term investments | $24.3M | $51.1M | $11.6M | $77.7M |
| Accounts receivable | $2.4B | $2.1B | $2.0B | $2.1B |
| Inventories | $160.6M | $134.6M | $143.1M | $109.1M |
| Contract assets and other receivables | $494.4M | $383.2M | $422.7M | $414.0M |
| Prepaid and other current assets | $156.3M | $122.9M | $102.6M | $78.8M |
| Income tax receivable | $49.9M | $27.5M | $6.4M | $4.6M |
| Total current assets | $4.1B | $3.7B | $3.1B | $3.2B |
| Property and equipment, net of accumulated depreciation | $2.8B | $2.9B | $3.1B | $3.3B |
| Operating lease right-of-use assets | $2.4B | $2.4B | $2.5B | $2.7B |
| Intangible assets, net of accumulated amortization | $222.1M | $197.4M | $203.2M | $182.7M |
| Equity method and other investments | $157.2M | $336.7M | $545.8M | $231.1M |
| Long-term investments | $41.0M | $33.7M | $47.9M | $44.3M |
| Other long-term assets | $246.5M | $261.7M | $271.3M | $315.6M |
| Goodwill | $7.5B | $7.4B | $7.1B | $7.1B |
| Assets, Total | $17.5B | $17.3B | $16.9B | $16.9B |
| Accounts payable | $696.1M | $547.2M | $514.5M | $479.8M |
| Other liabilities | $893.0M | $934.1M | $828.9M | $802.5M |
| Accrued compensation and benefits | $793.5M | $800.5M | $752.6M | $692.7M |
| Current portion of operating lease liabilities | $425.5M | $410.4M | $394.4M | $395.4M |
| Current portion of long-term debt | $109.2M | $270.9M | $123.3M | $231.4M |
| Income tax payable | $24.4M | $10.3M | $28.5M | $18.0M |
| Due to Related Party | $199.9M | — | — | — |
| Total current liabilities | $3.1B | $3.0B | $2.6B | $2.6B |
| Long-term operating lease liabilities | $2.2B | $2.2B | $2.3B | $2.5B |
| Long-term debt | $10.2B | $9.2B | $8.3B | $8.7B |
| Other long-term liabilities | $83.5M | $169.6M | $183.1M | $105.2M |
| Deferred income taxes | $756.9M | $665.4M | $726.2M | $782.8M |
| Total liabilities | $16.3B | $15.2B | $14.2B | $14.7B |
| Noncontrolling interests subject to put provisions | $1.5B | $1.7B | $1.5B | $1.3B |
| Preferred Stock, Value, Issued | $0 | $0 | $0 | $0 |
| Common Stock, Value, Issued | $69.0K | $90.0K | $89.0K | $90.0K |
| Additional paid-in capital | $0 | $286.3M | $509.8M | $606.9M |
| Accumulated (deficit) earnings | ($328.4M) | $1.5B | $598.3M | $174.5M |
| Treasury Stock, Value | ($199.9M) | ($1.4B) | — | — |
| Accumulated other comprehensive loss | ($122.8M) | ($310.8M) | ($52.1M) | ($69.2M) |
| Total DaVita Inc. shareholders' equity (deficit) | ($651.1M) | $121.1M | $1.1B | $712.3M |
| Noncontrolling interests not subject to put provisions | $277.4M | $274.7M | $188.0M | $163.6M |
| Total equity (deficit) | ($373.7M) | $395.9M | $1.2B | $875.9M |
| Total liabilities and shareholders' equity | $17.5B | $17.3B | $16.9B | $16.9B |
| Preferred stock, par value (in usd per share) | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred stock, shares authorized (in shares) | 5.0M | 5.0M | 5.0M | 5.0M |
| Preferred stock, issued (in shares) | 0 | 0 | 0 | 0 |
| Common stock, par value (in usd per share) | $0.00 | $0.00 | $0.00 | $0.00 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and Cash Equivalent | $669.0M | $644.2M | $706.0M | $708.4M |
| Restricted Cash and Cash Equivalent | $82.9M | $82.2M | $89.5M | $88.5M |
| Short-term investments | $19.9M | $22.3M | $30.5M | $31.0M |
| Accounts receivable | $2.5B | $2.5B | $2.3B | $2.4B |
| Inventories | $151.5M | $141.6M | $139.1M | $146.3M |
| Contract assets and other receivables | $565.6M | $517.7M | $521.9M | $477.2M |
| Prepaid and other current assets | $149.1M | $159.6M | $161.0M | $110.3M |
| Income tax receivable | $84.6M | $35.8M | $130.6M | $84.8M |
| Total current assets | $4.2B | $4.1B | $4.1B | $4.1B |
| Property and equipment, net | $2.7B | $2.8B | $2.9B | $2.9B |
| Operating lease right-of-use assets | $2.4B | $2.4B | $2.3B | $2.3B |
| Intangible assets, net | $228.8M | $229.0M | $219.7M | $211.7M |
| Equity method and other investments | $183.8M | $167.4M | $259.4M | $303.1M |
| Long-term investments | $38.4M | $39.5M | $40.1M | $38.7M |
| Other long-term assets | $298.5M | $267.0M | $204.5M | $192.7M |
| Goodwill | $7.6B | $7.6B | $7.5B | $7.5B |
| Total assets | $17.7B | $17.5B | $17.6B | $17.5B |
| Accounts payable | $715.9M | $691.3M | $655.6M | $594.4M |
| Other liabilities | $827.0M | $799.4M | $934.0M | $921.2M |
| Accrued compensation and benefits | $694.8M | $708.0M | $851.9M | $686.2M |
| Current portion of operating lease liabilities | $439.5M | $432.2M | $432.0M | $429.3M |
| Current portion of long-term debt | $117.2M | $112.7M | $62.9M | $182.4M |
| Income tax payable | $24.6M | $37.4M | $26.4M | $19.7M |
| Due to Related Party | $36.5M | $86.5M | $54.3M | $100.3M |
| Total current liabilities | $2.9B | $2.9B | $3.0B | $2.9B |
| Long-term operating lease liabilities | $2.2B | $2.2B | $2.1B | $2.1B |
| Long-term debt | $10.7B | $10.5B | $10.2B | $10.1B |
| Other long-term liabilities | $99.1M | $88.9M | $172.2M | $156.5M |
| Deferred income taxes | $825.7M | $818.9M | $742.5M | $646.2M |
| Total liabilities | $16.6B | $16.5B | $16.2B | $15.9B |
| Noncontrolling interests subject to put provisions | $1.6B | $1.5B | $1.6B | $1.7B |
| Preferred Stock, Value, Issued | $0 | $0 | $0 | $0 |
| Common Stock, Value, Issued | $69.0K | $69.0K | $91.0K | $91.0K |
| Additional paid-in capital | $0 | $0 | $401.8M | $356.9M |
| Accumulated earnings (deficit) | $81.2M | ($179.2M) | $2.0B | $1.9B |
| Treasury Stock, Value | ($787.8M) | ($489.4M) | ($2.9B) | ($2.5B) |
| Accumulated other comprehensive loss | ($58.6M) | ($87.0M) | ($116.2M) | ($137.8M) |
| Total DaVita Inc. shareholders' equity deficit | ($765.1M) | ($755.5M) | ($571.9M) | ($369.6M) |
| Noncontrolling interests not subject to put provisions | $283.1M | $279.2M | $267.6M | $261.7M |
| Total equity deficit | ($482.0M) | ($476.3M) | ($304.2M) | ($108.0M) |
| Total liabilities and equity | $17.7B | $17.5B | $17.6B | $17.5B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income | $1.1B | $1.3B | $957.0M | $781.6M |
| Depreciation and amortization | $715.3M | $723.9M | $745.4M | $732.6M |
| Impairment charges | $0 | $0 | $26.1M | — |
| Loss on extinguishment of debt | $12.4M | $12.5M | $7.1M | — |
| Stock-based compensation expense | $140.0M | $102.8M | $112.4M | $95.4M |
| Deferred income taxes | $86.6M | ($57.8M) | ($39.4M) | ($75.7M) |
| Equity investment loss, net | $134.3M | $115.8M | $64.8M | $8.8M |
| Gain on changes in ownership interests | $0 | ($109.5M) | — | — |
| Other non-cash (gains) and losses, net | ($17.5M) | $13.4M | ($8.9M) | $21.7M |
| Accounts receivable | ($210.6M) | ($29.8M) | $172.4M | ($148.4M) |
| Inventories | ($19.9M) | $17.9M | ($32.1M) | ($757.0K) |
| Other current assets | ($124.3M) | $36.8M | ($43.4M) | $27.5M |
| Other long-term assets | ($40.3M) | ($67.0M) | ($5.8M) | ($50.5M) |
| Accounts payable | $128.3M | $1.7M | $26.9M | $87.5M |
| Accrued compensation and benefits | ($24.0M) | $14.7M | $56.2M | $34.5M |
| Other current liabilities | ($30.0M) | $46.7M | $27.1M | $90.0M |
| Income taxes | $50.2M | ($44.2M) | $1.6M | ($24.1M) |
| Other long-term liabilities | $7.3M | ($6.7M) | ($8.2M) | ($15.6M) |
| Net Cash Provided by (Used in) Operating Activities, Total | $1.9B | $2.0B | $2.1B | $1.6B |
| Additions of property and equipment | ($575.9M) | ($555.4M) | ($568.0M) | ($603.4M) |
| Acquisitions | ($117.5M) | $246.1M | ($26.4M) | ($57.3M) |
| Proceeds from asset and business sales | $34.2M | $25.9M | $30.6M | $117.6M |
| Purchase of debt investments held-to-maturity | ($16.4M) | ($15.3M) | ($37.2M) | ($129.8M) |
| Purchase of other debt and equity investments | ($6.0M) | ($9.1M) | ($9.6M) | ($3.6M) |
| Proceeds from debt investments held-to-maturity | $45.4M | $22.6M | $99.6M | $71.1M |
| Proceeds from sale of other debt and equity investments | $6.7M | $4.6M | $10.4M | $3.8M |
| Purchase of equity method investments | ($27.0M) | ($5.2M) | ($276.2M) | ($31.9M) |
| Distributions from equity method investments | $1.5M | $6.7M | $4.9M | $4.0M |
| Net Cash Provided by (Used in) Investing Activities, Total | ($654.9M) | ($771.4M) | ($771.8M) | ($630.3M) |
| Borrowings | $5.6B | $6.6B | $2.5B | $2.4B |
| Payments on long-term debt | ($4.8B) | ($5.5B) | ($3.0B) | ($2.4B) |
| Deferred and debt related financing costs | ($53.8M) | ($50.9M) | ($69.8M) | — |
| Purchase Of Treasury Stock From Related Party | ($484.6M) | — | — | — |
| Purchase of treasury stock | ($1.3B) | ($1.4B) | ($272.2M) | ($802.2M) |
| Distributions to noncontrolling interests | ($324.3M) | ($337.0M) | ($280.9M) | ($267.9M) |
| Net proceeds from issuance of common stock under employee stock plans | $23.3M | $20.5M | — | — |
| Payment, Tax Withholding, Share-Based Payment Arrangement | ($35.3M) | ($134.0M) | — | — |
| Contributions from noncontrolling interests | $7.1M | $14.5M | $14.8M | $14.8M |
| Proceeds from sales of additional noncontrolling interests | $3.8M | $860.0K | $51.0M | $3.7M |
| Purchases of noncontrolling interests | ($26.0M) | ($54.0M) | ($12.6M) | ($20.8M) |
| Net cash used in financing activities | ($1.4B) | ($816.9M) | ($1.2B) | ($1.1B) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $21.2M | ($18.5M) | $8.9M | ($29.1M) |
| Less: Net increase (decrease) in cash, cash equivalents and restricted cash | ($122.1M) | $415.2M | $125.6M | ($216.0M) |
| Cash, cash equivalents and restricted cash of continuing operations at beginning of the year | $879.8M | $464.6M | $339.0M | $555.0M |
| Cash, cash equivalents and restricted cash of continuing operations at end of the year | $757.7M | $879.8M | $464.6M | $339.0M |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income | $618.3M | $275.0M | $747.7M | $507.4M |
| Depreciation and amortization | $345.6M | $177.8M | $528.6M | $351.2M |
| Stock-based compensation expense | $54.2M | $28.2M | $101.6M | $62.6M |
| Deferred income taxes | $53.4M | $54.8M | $69.0M | ($9.8M) |
| Equity investment loss, net | $2.4M | ($30.0K) | $91.5M | $47.7M |
| Other non-cash losses, net | $16.7M | $6.7M | $11.5M | $6.9M |
| Accounts receivable | ($24.2M) | ($29.8M) | ($144.7M) | ($288.4M) |
| Inventories | $11.3M | $20.3M | $913.0K | ($9.6M) |
| Other current assets | ($58.3M) | ($22.8M) | ($153.4M) | ($70.9M) |
| Other long-term assets | ($22.8M) | ($2.6M) | ($21.0K) | $3.0M |
| Accounts payable | $7.6M | ($23.8M) | $97.9M | $35.6M |
| Accrued compensation and benefits | ($108.3M) | ($88.3M) | $19.3M | ($125.4M) |
| Other current liabilities | ($55.8M) | ($96.9M) | $16.5M | ($3.6M) |
| Income taxes | ($32.5M) | $27.1M | ($30.6M) | $9.5M |
| Other long-term liabilities | $3.3M | ($5.0M) | ($14.2M) | ($11.9M) |
| Net cash provided by operating activities | $810.9M | $320.8M | $1.3B | $504.2M |
| Additions of property and equipment | ($271.8M) | ($102.0M) | ($430.4M) | ($264.3M) |
| Acquisitions | ($38.5M) | ($33.9M) | ($118.3M) | ($10.6M) |
| Proceeds from asset and business sales | $4.4M | $3.7M | $32.3M | $22.4M |
| Purchase of debt investments held-to-maturity | ($298.0K) | ($290.0K) | ($15.8M) | ($27.5M) |
| Purchase of other debt and equity investments | ($12.9M) | ($9.7M) | ($3.4M) | ($3.0M) |
| Proceeds from debt investments held-to-maturity | $942.0K | $942.0K | $38.1M | $48.0M |
| Proceeds from sale of other debt and equity investments | $4.4M | $4.3M | $6.7M | $6.4M |
| Purchase of equity method investments | ($19.6M) | ($2.3M) | ($2.5M) | ($2.1M) |
| Distributions from equity method investments | $109.0K | $109.0K | $1.5M | $1.5M |
| Net cash used in investing activities | ($333.3M) | ($139.1M) | ($491.8M) | ($229.3M) |
| Borrowings | $2.8B | $1.3B | $4.7B | $4.2B |
| Payments on long-term debt | ($2.3B) | ($917.1M) | ($3.9B) | ($3.4B) |
| Deferred and debt related financing costs | ($4.6M) | ($2.9M) | ($26.4M) | ($25.1M) |
| Purchase Of Treasury Stock From Related Party | ($382.8M) | ($199.9M) | ($430.3M) | ($200.3M) |
| Other purchases of treasury stock | ($377.9M) | ($196.4M) | ($1.0B) | ($793.8M) |
| Distributions to noncontrolling interests | ($149.9M) | ($85.4M) | ($232.7M) | ($151.1M) |
| Net proceeds from issuance of common stock under employee stock plans | $5.9M | $2.4M | $17.6M | $8.9M |
| Payment of tax withholdings on net share settlements of equity awards | ($63.8M) | ($63.2M) | ($33.8M) | ($30.5M) |
| Contributions from noncontrolling interests | $4.2M | $4.0M | $4.0M | $2.6M |
| Proceeds from sales of additional noncontrolling interests | $0 | — | $169.0K | $169.0K |
| Purchases of noncontrolling interests | ($18.6M) | ($18.1M) | ($16.4M) | ($5.4M) |
| Net cash used in financing activities | ($483.5M) | ($213.3M) | ($960.3M) | ($378.1M) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $80.0K | $259.0K | $21.9M | $20.3M |
| Net decrease in cash, cash equivalents and restricted cash | ($5.9M) | ($31.3M) | ($84.4M) | ($82.9M) |
| Cash, cash equivalents and restricted cash at beginning of the year | $757.7M | $757.7M | $879.8M | $879.8M |
| Cash, cash equivalents and restricted cash at end of the period | $751.9M | $726.4M | $795.4M | $797.0M |
DaVita Inc. score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.